Likewise, HMGB1/TLR4/NF-κB signaling mediates metastasis and enhances inflammatory cytokine production in breast cancer [204], while drug-resistant myeloma cells exhibit increased HMGB1 release, whereby silencing HMGB1 diminishes NF-κB phosphorylation and restores drug sensitivity [207]. The gene discussed is NFKB1; the disease is plasma cell myeloma.